U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06920446) titled 'UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic Anemia' on April 02.
Brief Summary: This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Autoimmune hemolytic anemia. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.
Study Start Date: April 03
Study Type: INTERVENTIONAL
Condition:
Relapsed / Refractory Autoimmune Hemolytic Anemia
Intervention:
BIOLOGICAL: UCAR T-cell group
A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
Recruitm...